Phase II Dose Titration Study of Regorafenib for Patients With Unresectable Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
  • [41] Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503)
    Iwasa, Satoru
    Okita, Natsuko
    Kuchiba, Aya
    Ogawa, Gakuto
    Kawasaki, Mamiko
    Nakamura, Kenichi
    Shoji, Hirokazu
    Honma, Yoshitaka
    Takashima, Atsuo
    Kato, Ken
    Hamaguchi, Tetsuya
    Boku, Narikazu
    Yamada, Yasuhide
    ESMO OPEN, 2020, 5 (04)
  • [42] Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study
    Nakashima, Masayuki
    Ide, Kazuki
    Kawakami, Koji
    TARGETED ONCOLOGY, 2019, 14 (03) : 295 - 306
  • [43] Comparison of Standard Initial Dose and Reduced Initial Dose Regorafenib for Colorectal Cancer Patients: A Retrospective Cohort Study
    Masayuki Nakashima
    Kazuki Ide
    Koji Kawakami
    Targeted Oncology, 2019, 14 : 295 - 306
  • [44] A phase II study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer
    Hyodo, Ichinosuke
    Shirao, Kuniaki
    Doi, Toshihiko
    Hatake, Kiyohiko
    Arai, Yasuaki
    Yamaguchi, Kensei
    Tamura, Takao
    Takemiya, Shoji
    Takiuchi, Hiroya
    Nakagawa, Kazuhiko
    Mishima, Hideyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (07) : 410 - 417
  • [45] A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with metastatic colorectal cancer after failure of standard chemotherapy.
    Huang, Mingzhu
    Chen, Zhiyu
    Wang, Yusheng
    Zhu, Xiaodong
    Zhang, Wen
    Zhang, Xiaowei
    Zhao, Xiaoying
    Qiu, Lixin
    Wang, Chenchen
    Guo, Weijian
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [46] A Phase II Study of High-Dose Cetuximab plus Irinotecan in Colorectal Cancer Patients with KRAS Wild-Type Tumors Who Progressed after Standard Dose of Cetuximab plus Irinotecan
    Fora, Ahmad A.
    McMahon, Jeanne A.
    Wilding, Greg
    Groman, Adrienne
    Ma, Wen Wee
    Romano, Karen S.
    Fakih, Marwan G.
    ONCOLOGY, 2013, 84 (04) : 210 - 213
  • [47] Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)
    Arora, Sukeshi Patel
    Tenner, Laura
    Sarantopoulos, John
    Morris, Jay
    Liu, Qianqian
    Mendez, Jenny A.
    Curiel, Tyler
    Michalek, Joel
    Mahalingam, Devalingam
    BRITISH JOURNAL OF CANCER, 2022, 127 (06) : 1153 - 1161
  • [48] Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)
    Sukeshi Patel Arora
    Laura Tenner
    John Sarantopoulos
    Jay Morris
    Qianqian Liu
    Jenny A. Mendez
    Tyler Curiel
    Joel Michalek
    Devalingam Mahalingam
    British Journal of Cancer, 2022, 127 : 1153 - 1161
  • [49] Phase II study of oxaliplatin in patients with unresectable, metastatic or recurrent hepatocellular cancer
    Yen, Y
    Doroshow, J
    Leong, L
    Lim, D
    Wagman, L
    Morgan, R
    Frankel, P
    Lenz, H
    Gandara, D
    Shibata, S
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 355S - 355S
  • [50] Phase II study of ruxolitinib with regorafenib for relapsed/refractory (r/r) metastatic colorectal cancer (mCRC).
    Fogelman, David R.
    Kochenderfer, Mark D.
    Saylors, Gene Brian
    Braiteh, Fadi S.
    Nemunaitis, John J.
    Cohn, Allen Lee
    O'Neill, Peter
    Zhou, Li
    Switzky, Julie C.
    Assad, Albert
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345